Antibodies News and Research

RSS

Molecular simulations provide insight into SARS-CoV-2 variant RBD interactions with ACE2 and mAbs

Researchers aimed to understand the relationship between the SARS-CoV-2 receptor-binding domain and both human receptors and therapeutic targets.

3 Feb 2022

Studying the efficacy of a SARS-CoV-2 vaccine booster dose

In a new study, a team of researchers assessed the efficacy of booster doses of Ad26.COV2.S (Jansen) SARS-CoV-2 vaccine.

3 Feb 2022

Exploring human milk oligosaccharides as a method of COVID-19 prevention

New research was conducted to ascertain whether antiviral and immunomodulatory activities of human milk oligosaccharides can be efficacious in the prevention and treatment against COVID-19.

3 Feb 2022

Neutralizing antibodies against SARS-CoV-2 variants induced by homologous and heterologous COVID-19 booster vaccination

In this study, scientists focused on identifying tentative cut-offs for large-scale evaluations of immune protection against SARS-CoV-2 and its variants.

3 Feb 2022

Nanoparticle vaccine effective against eight SARS-CoV-2 variants in non-human primates

Researchers demonstrate that SARS-CoV-2 RBD-based nanoparticle vaccine induces neutralizing antibodies against SARS-CoV-2 variants.

2 Feb 2022

Antigenic map of SARS-CoV-2 variants reveals amino acid substitutions that govern immune escape and immunodominance

Researchers use antigenic cartography to analyze cross-reactivity patterns of eight groups of human sera on a panel of SARS-CoV-2 variants.

2 Feb 2022

Booster dose of Covaxin vaccine candidate neutralizes Omicron and Delta variants

Researchers evaluate the neutralization potential of sera samples from subjects boosted with the Covaxin against the SARS-CoV-2 Omicron variant.

2 Feb 2022

UK's world-leading human challenge study provides new insights into mild SARS-CoV-2 infections

Findings from the UK's world-leading human challenge study provide new insights into mild infections with SARS-CoV-2 in healthy young adults.

2 Feb 2022

NIAID's new pandemic preparedness efforts aim to characterize prototype and priority pathogens

As the global COVID-19 pandemic continues into its third year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is focusing on preparing for a range of other viral threats that could cause a public health emergency.

2 Feb 2022

Study discovers how long-term memory T cells are formed after SARS-CoV-2 exposure

Exposure to SARS-CoV-2 by infection or vaccination generates immune cells that provide long-term immunity. These long-lived memory T cells play a key role in preventing severe cases of Covid-19. Researchers at the University of Zurich have now discovered how these memory T cells form.

2 Feb 2022

The ability of individuals to cross-recognize the Omicron spike protein following vaccination or prior infection

Scientists studied the ability of T cells to react with the Omicron spike.

2 Feb 2022

Quantitative framework to investigate the dynamic mechanism of host immune response confronting SARS-CoV-2 infection

The authors highlight that they have created a quantitative framework that allows the dynamic mechanism of the immune response to SARS-CoV-2 to be properly investigated.

2 Feb 2022

Representative structures of SARS-CoV-2 and development of therapeutic agents for targeting these proteins

Researchers from China summarized the representative structures of SARS-CoV-2 proteins and discussed the development of novel therapeutic agents for targeting these proteins to treat and prevent COVID-19.

2 Feb 2022

Study reveals pet hamsters can acquire SARS-CoV-2 infection in real-life settings and transmit the virus back to humans

Researchers investigated the transmission of the SARS-CoV-2 Delta VOC from infected hamsters to humans.

2 Feb 2022

Study proposes Omicron variant may be derived from recombination of two early SARS-CoV-2 PANGO lineages

A recent study showed that the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant is a chimera of two earlier PANGO lineages of SARS-CoV-2.

2 Feb 2022

New nanoparticle SARS-CoV-2 vaccine shows stronger, broader, and more durable protection

The first generation of COVID-19 vaccines have been highly effective, but also have limitations: their efficacy can wane without a booster shot, and they may be less effective against some variants.

2 Feb 2022

Research supports the need for a 3rd mRNA COVID vaccine in patients taking immunosuppressants

New research posted to the medRxiv* preprint server finds patients with immune-mediated inflammatory diseases undergoing anti-TNF therapy had the greatest reduction of antibody levels three months after vaccination. In addition, they had weaker neutralization responses towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.

1 Feb 2022

COVID-19 vaccines induce robust cellular immune response against SARS-CoV-2 Omicron

A team of scientists from the United States has recently demonstrated that current coronavirus disease 2019 (COVID-19) vaccines induce robust spike-specific T cell responses against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

1 Feb 2022

Study confirms SARS-CoV-2 Omicron variant has a decreased ability to enter lung cells

A large multinational group of researchers has shown how the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has gained exceptional immune evasion properties but also a much lower propensity to enter cells such as those in lung alveoli, resulting in its reduced pathogenicity. Their paper is currently released as an unedited version of the manuscript prior to publication in the journal Nature.

1 Feb 2022

Study demonstrates substantial immune response in individuals infected with SARS-CoV-2 Omicron variant

Researchers analyze neutralizing antibodies against the SARS-CoV-2 VOCs with the sera of vaccinated individuals infected with the Omicron variant.

1 Feb 2022

Antibodies News and Research

Molecular simulations provide insight into SARS-CoV-2 variant RBD interactions with ACE2 and mAbs

Studying the efficacy of a SARS-CoV-2 vaccine booster dose

Exploring human milk oligosaccharides as a method of COVID-19 prevention

Neutralizing antibodies against SARS-CoV-2 variants induced by homologous and heterologous COVID-19 booster vaccination

Nanoparticle vaccine effective against eight SARS-CoV-2 variants in non-human primates

Antigenic map of SARS-CoV-2 variants reveals amino acid substitutions that govern immune escape and immunodominance

Booster dose of Covaxin vaccine candidate neutralizes Omicron and Delta variants

UK's world-leading human challenge study provides new insights into mild SARS-CoV-2 infections

NIAID's new pandemic preparedness efforts aim to characterize prototype and priority pathogens

Study discovers how long-term memory T cells are formed after SARS-CoV-2 exposure

The ability of individuals to cross-recognize the Omicron spike protein following vaccination or prior infection

Quantitative framework to investigate the dynamic mechanism of host immune response confronting SARS-CoV-2 infection

Representative structures of SARS-CoV-2 and development of therapeutic agents for targeting these proteins

Study reveals pet hamsters can acquire SARS-CoV-2 infection in real-life settings and transmit the virus back to humans

Study proposes Omicron variant may be derived from recombination of two early SARS-CoV-2 PANGO lineages

New nanoparticle SARS-CoV-2 vaccine shows stronger, broader, and more durable protection

Research supports the need for a 3rd mRNA COVID vaccine in patients taking immunosuppressants

COVID-19 vaccines induce robust cellular immune response against SARS-CoV-2 Omicron

Study confirms SARS-CoV-2 Omicron variant has a decreased ability to enter lung cells

Study demonstrates substantial immune response in individuals infected with SARS-CoV-2 Omicron variant

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News